12 HR oxymorphone hydrochloride 5 MG Extended Release Oral Tablet

Verify with CMS →

oxymorphone hydrochloride

RxCUI: 977923

Important: Drug coverage and costs vary by plan and location. Verify coverage directly with your Medicare plan before filling a prescription. This is informational data only and should not replace advice from your healthcare provider or pharmacist.
6.2%
Plan Coverage
316
Plans Covering
T3.1
Avg Tier
0%
Prior Auth Required

What the CMS Formulary Data Shows for 12 HR oxymorphone hydrochloride 5 MG Extended Release Oral Tablet

Per the CMS 2026 Part D formulary file, 12 HR oxymorphone hydrochloride 5 MG Extended Release Oral Tablet (RxNorm concept RXCUI 977923, generic name oxymorphone hydrochloride) appears on 21 distinct formulary files spanning 316 Medicare Part D plan offerings - 6.2% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 3.1.

Real-world access to 12 HR oxymorphone hydrochloride 5 MG Extended Release Oral Tablet depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 85.7% apply quantity limits.

Medicare Part D spending dashboard figures are not published for this drug. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry 12 HR oxymorphone hydrochloride 5 MG Extended Release Oral Tablet today.

Coverage Details

Formularies covering
21
Plans covering
316
Coverage rate
6.2%
Tier range
Tier 1 – Tier 4
Average tier
Tier 3, Preferred Brand

Restrictions

Prior authorization required
0% of formularies
Step therapy required
0% of formularies
Quantity limits
85.7% of formularies

Tier Distribution Across Plans

13 plans
Tier 1, Preferred Generic
9 plans
Tier 2, Generic
2 plans
Tier 3, Preferred Brand
76 plans
Tier 4, Non-Preferred

Standalone Drug Plans (PDP) Covering 12 HR oxymorphone hydrochloride 5 MG Extended Release Oral Tablet

9 standalone prescription drug plans include this drug.

Plan Insurer Tier PA ST Premium States
HealthSpring Assurance Rx (PDP) MEDCO CONTAINMENT LIFE AND MEDCO CONTAINMENT NY T4 No No $0 -
HealthSpring Assurance Rx (PDP) MEDCO CONTAINMENT LIFE AND MEDCO CONTAINMENT NY T4 No No $0 -
HealthSpring Assurance Rx (PDP) MEDCO CONTAINMENT LIFE AND MEDCO CONTAINMENT NY T4 No No $0 -
HealthSpring Assurance Rx (PDP) MEDCO CONTAINMENT LIFE AND MEDCO CONTAINMENT NY T4 No No $0 -
HealthSpring Assurance Rx (PDP) MEDCO CONTAINMENT LIFE AND MEDCO CONTAINMENT NY T4 No No $0 -
HealthSpring Assurance Rx (PDP) MEDCO CONTAINMENT LIFE AND MEDCO CONTAINMENT NY T4 No No $0 -
HealthSpring Assurance Rx (PDP) MEDCO CONTAINMENT LIFE AND MEDCO CONTAINMENT NY T4 No No $0 -
HealthSpring Assurance Rx (PDP) MEDCO CONTAINMENT LIFE AND MEDCO CONTAINMENT NY T4 No No $0 -
HealthSpring Assurance Rx (PDP) MEDCO CONTAINMENT LIFE AND MEDCO CONTAINMENT NY T4 No No $0 -

Medicare Advantage Plans (MA-PD) Covering 12 HR oxymorphone hydrochloride 5 MG Extended Release Oral Tablet

91 Medicare Advantage plans with Part D drug coverage include this drug.

Plan Insurer Tier PA Premium States
PHP (HMO C-SNP) AIDS HEALTHCARE FOUNDATION T1 No $0 CA
VNS Health Total (HMO D-SNP) VNS CHOICE T1 No $0 NY
CalOptima Health OneCare Complete (HMO D-SNP) ORANGE COUNTY HEALTH AUTHORITY T1 No $0 CA
Highmark Wholecare Medicare Assured Diamond (HMO D-SNP) GATEWAY HEALTH PLAN, INC. T1 No $0 PA
Highmark Wholecare Medicare Assured Diamond (HMO D-SNP) GATEWAY HEALTH PLAN, INC. T1 No $0 PA
Highmark Health Options Duals (HMO D-SNP) HIGHMARK HEALTH OPTIONS WEST VIRGINIA INC. T1 No $0 WV
Highmark Health Options Duals (HMO D-SNP) HIGHMARK BCBSD, INC. T1 No $0 DE
Gold Dialysis & Kidney Complete (HMO-POS C-SNP) GOLD KIDNEY OF FLORIDA INC T1 No $4.80 FL
Highmark Wholecare Medicare Assured Ruby (HMO D-SNP) GATEWAY HEALTH PLAN, INC. T1 No $13.10 PA
Gold Dialysis & Kidney Complete (HMO-POS C-SNP) GOLD KIDNEY OF ARIZONA T1 No $17.00 AZ
Highmark Wholecare Medicare Assured Ruby (HMO D-SNP) GATEWAY HEALTH PLAN, INC. T1 No $17.60 PA
Highmark Health Options Duals Select (HMO D-SNP) HIGHMARK BCBSD, INC. T1 No $31.20 DE
VNS Health EasyCare Plus (HMO D-SNP) VNS CHOICE T1 No $51.60 NY
Gold Heart & Diabetes (HMO-POS C-SNP) GOLD KIDNEY OF FLORIDA INC T2 No $0 FL
Gold Heart & Diabetes Complete (HMO-POS C-SNP) GOLD KIDNEY OF FLORIDA INC T2 No $0 FL
Gold Dialysis & Kidney (HMO-POS C-SNP) GOLD KIDNEY OF FLORIDA INC T2 No $0 FL
Gold Health (HMO-POS C-SNP) GOLD KIDNEY OF FLORIDA INC T2 No $0 FL
Gold Dialysis & Kidney (HMO-POS C-SNP) GOLD KIDNEY OF FLORIDA INC T2 No $0 FL
Gold Heart & Diabetes (HMO-POS C-SNP) GOLD KIDNEY OF ARIZONA T2 No $0 AZ
Gold Dialysis & Kidney (HMO-POS C-SNP) GOLD KIDNEY OF ARIZONA T2 No $0 AZ
Gold Heart & Diabetes (HMO-POS C-SNP) GOLD KIDNEY OF ARIZONA T2 No $0 AZ
Gold Dialysis & Kidney (HMO-POS C-SNP) GOLD KIDNEY OF ARIZONA T2 No $0 AZ
VillageCareMAX Medicare Health Advantage Plan (HMO D-SNP) VILLAGE SENIOR SERVICES CORPORATION T3 No $0 NY
VillageCareMAX Medicare Total Advantage Plan (HMO D-SNP) VILLAGE SENIOR SERVICES CORPORATION T3 No $0 NY
Medicare BlueEssential (PPO) EXCELLUS HEALTH PLAN, INC. T4 No $0 NY
Medicare BlueActive (PPO) EXCELLUS HEALTH PLAN, INC. T4 No $0 NY
Medicare BlueVital (PPO) EXCELLUS HEALTH PLAN, INC. T4 No $0 NY
Univera SeniorChoice Basic (HMO) EXCELLUS HEALTH PLAN, INC. T4 No $0 NY
Univera SeniorChoice Extra (HMO) EXCELLUS HEALTH PLAN, INC. T4 No $0 NY
Medicare Blue Choice Core (HMO) EXCELLUS HEALTH PLAN, INC. T4 No $0 NY
HAP Medicare Explore (PPO) ALLIANCE HEALTH AND LIFE INSURANCE COMPANY T4 No $0 MI
HAP Medicare Prime (PPO) ALLIANCE HEALTH AND LIFE INSURANCE COMPANY T4 No $0 MI
HAP Medicare Connect (HMO) HEALTH ALLIANCE PLAN OF MICHIGAN T4 No $0 MI
HAP Medicare Complete Duals (HMO D-SNP) HEALTH ALLIANCE PLAN OF MICHIGAN T4 No $0 MI
HAP Medicare Superior (HMO) HEALTH ALLIANCE PLAN OF MICHIGAN T4 No $0 MI
Henry Ford Select (HMO) HEALTH ALLIANCE PLAN OF MICHIGAN T4 No $0 MI
Univera Medicare Dual (HMO D-SNP) EXCELLUS HEALTH PLAN COMMUNITY CARE LLC T4 No $0 NY
Medicare Blue Dual (HMO D-SNP) EXCELLUS HEALTH PLAN COMMUNITY CARE LLC T4 No $0 NY
HealthSpring Preferred (HMO) BRAVO HEALTH PENNSYLVANIA, INC. T4 No $0 AZ
HealthSpring Alliance (HMO) BRAVO HEALTH PENNSYLVANIA, INC. T4 No $0 AZ
HealthSpring Preferred Savings (HMO) BRAVO HEALTH PENNSYLVANIA, INC. T4 No $0 AZ
HealthSpring Preferred Full Savings (HMO) BRAVO HEALTH PENNSYLVANIA, INC. T4 No $0 AZ
HealthSpring Preferred GA (HMO) HEALTHSPRING LIFE & HEALTH INSURANCE COMPANY, INC. T4 No $0 GA
HealthSpring Preferred (HMO) HEALTHSPRING LIFE & HEALTH INSURANCE COMPANY, INC. T4 No $0 GA
HealthSpring Preferred (HMO) HEALTHSPRING LIFE & HEALTH INSURANCE COMPANY, INC. T4 No $0 GA
HealthSpring Preferred (HMO) HEALTHSPRING LIFE & HEALTH INSURANCE COMPANY, INC. T4 No $0 GA
HealthSpring Preferred (HMO) HEALTHSPRING LIFE & HEALTH INSURANCE COMPANY, INC. T4 No $0 GA
HealthSpring Preferred (HMO) HEALTHSPRING LIFE & HEALTH INSURANCE COMPANY, INC. T4 No $0 GA
HealthSpring Preferred (HMO) HEALTHSPRING LIFE & HEALTH INSURANCE COMPANY, INC. T4 No $0 GA
HealthSpring Preferred Savings (HMO) HEALTHSPRING LIFE & HEALTH INSURANCE COMPANY, INC. T4 No $0 GA

Frequently Asked Questions

Is 12 HR oxymorphone hydrochloride 5 MG Extended Release Oral Tablet covered by Medicare Part D?

Yes, 12 HR oxymorphone hydrochloride 5 MG Extended Release Oral Tablet is covered by 316 Medicare Part D plans (6.2% of all Part D formularies).

What tier is 12 HR oxymorphone hydrochloride 5 MG Extended Release Oral Tablet on Medicare Part D plans?

12 HR oxymorphone hydrochloride 5 MG Extended Release Oral Tablet averages Tier 3.1 across Part D plans, ranging from Tier 1 to Tier 4.

Does 12 HR oxymorphone hydrochloride 5 MG Extended Release Oral Tablet require prior authorization?

0% of Part D formularies require prior authorization for 12 HR oxymorphone hydrochloride 5 MG Extended Release Oral Tablet. Step therapy: 0%. Quantity limits: 85.7%.

Data sourced from the Centers for Medicare & Medicaid Services (CMS). See our methodology for details. Retrieved and formatted by PlainMedicare Editorial